Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ...
Demand for kidney transplants in the United States exceeds that for all other organs combined. Against that backdrop, Emory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results